Search alternatives:
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
nm decrease » nn decrease (Expand Search), _ decrease (Expand Search), gy decreased (Expand Search)
we decrease » _ decrease (Expand Search), nn decrease (Expand Search), teer decrease (Expand Search)
a decrease » _ decrease (Expand Search), _ decreased (Expand Search), _ decreases (Expand Search)
-
6741
-
6742
-
6743
Initial treatment regimen.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
6744
Patients baseline characteristics.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
6745
Overall survival.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
6746
Progression-free survival by treatment.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
6747
Maintenance regimen and adverse event management.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
6748
BCC-specific survival.
Published 2024“…Hedgehog inhibition (HHI) with vismodegib or sonidegib induces a 50–60% response rate. Long-term toxicity includes muscle spasms and weight loss leading to dose decreases. …”
-
6749
-
6750
Table_4_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX
Published 2020“…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”
-
6751
Table_1_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX
Published 2020“…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”
-
6752
Table_2_Clinical Features of 50 Patients With Primary Adrenal Lymphoma.DOCX
Published 2020“…<p>Background and Objective: Primary adrenal lymphoma is a rare, progressive, easily misdiagnosed adrenal tumor with a poor prognosis. …”
-
6753
-
6754
-
6755
-
6756
Top 50 results of a commercial kinase screen using [γ<sup>33</sup>]-ATP and human obscurin SH3-DH as substrates.
Published 2023“…While MST2 addition resulted in strong and saturable phosphorylation, TBK1 led to much lower phosphorylation levels and CaMK4 addition led to an intermediate phosphorylation level exhibiting a biphasic behaviour with phosphorylation levels decreasing at higher substrate concentrations. …”
-
6757
Biphasic <i>in vitro</i> maturation with C-type natriuretic peptide enhances the developmental competence of juvenile-goat oocytes
Published 2019“…In experiment 2, the same CNP concentrations were assessed plus 10 nM estradiol, the known upstream agonist activating expression of NPR2, the exclusive receptor of CNP. …”
-
6758
-
6759
-
6760